Posted by Michael Wonder on 31 Jan 2018
Industry needs clarity to invest in Australia
31 January 2018 - Medicines Australia welcomes the release of the 2030 plan by Innovation and Science Australia but seeks clarification on R&D tax incentive.
Milton Catelin, Chief Executive of Medicines Australia stressed the need to continue to improve Australia’s capabilities in innovation and commercialisation and welcomes the Governments renewed commitment to innovation as a driver of economic growth and prosperity.
“A long term vision is paramount in order to cement Australia as a top destination for investment in research and development in the latest breakthroughs, said Mr Catelin.
